1. Home
  2. CUE vs BRIA Comparison

CUE vs BRIA Comparison

Compare CUE & BRIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • BRIA
  • Stock Information
  • Founded
  • CUE 2014
  • BRIA 2011
  • Country
  • CUE United States
  • BRIA Singapore
  • Employees
  • CUE N/A
  • BRIA N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • BRIA
  • Sector
  • CUE Health Care
  • BRIA
  • Exchange
  • CUE Nasdaq
  • BRIA NYSE
  • Market Cap
  • CUE 91.9M
  • BRIA 86.3M
  • IPO Year
  • CUE 2018
  • BRIA 2024
  • Fundamental
  • Price
  • CUE $1.27
  • BRIA $3.32
  • Analyst Decision
  • CUE Strong Buy
  • BRIA
  • Analyst Count
  • CUE 5
  • BRIA 0
  • Target Price
  • CUE $5.00
  • BRIA N/A
  • AVG Volume (30 Days)
  • CUE 277.1K
  • BRIA 28.8K
  • Earning Date
  • CUE 03-10-2025
  • BRIA 02-19-2025
  • Dividend Yield
  • CUE N/A
  • BRIA N/A
  • EPS Growth
  • CUE N/A
  • BRIA N/A
  • EPS
  • CUE N/A
  • BRIA 92.24
  • Revenue
  • CUE $9,532,000.00
  • BRIA $55,755,669.00
  • Revenue This Year
  • CUE $73.11
  • BRIA N/A
  • Revenue Next Year
  • CUE $11.02
  • BRIA N/A
  • P/E Ratio
  • CUE N/A
  • BRIA $0.04
  • Revenue Growth
  • CUE 149.53
  • BRIA 8.03
  • 52 Week Low
  • CUE $0.45
  • BRIA $3.18
  • 52 Week High
  • CUE $2.58
  • BRIA $4.38
  • Technical
  • Relative Strength Index (RSI)
  • CUE 49.50
  • BRIA N/A
  • Support Level
  • CUE $1.27
  • BRIA N/A
  • Resistance Level
  • CUE $1.50
  • BRIA N/A
  • Average True Range (ATR)
  • CUE 0.12
  • BRIA 0.00
  • MACD
  • CUE -0.01
  • BRIA 0.00
  • Stochastic Oscillator
  • CUE 53.73
  • BRIA 0.00

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.

About BRIA BRILLIA INC

BrilliA Inc is engaged in business of sales and marketing of lingerie's products including bra, panty and body suit, mainly serving the American, European and other markets.

Share on Social Networks: